Drug Development

α7烟碱型乙酰胆碱受体的选择性正变构调节剂Uci-40083 (Alpha7 NAChR)，由加州大学欧文分校的团队设计并表征。它的合成用于临床 NCDDDG项目中的试验和临床前实验将由药物化学家在 Newport Science Inc.，由我们的团队监督。我们将与Newport Science Inc.合作，进行 人体使用制剂所需的含量测定和稳定性研究。我们还将与Newport合作 科学公司支持第一阶段和第二阶段临床试验的血浆和尿液分析。因为 第二阶段试验将在接受抗精神病药物治疗的精神分裂症患者身上进行，许多 其中吸烟的人，加州大学欧文分校的团队将进行临床前动物模型研究，以确定 乌拉地平-40083对慢性尼古丁(模拟吸烟)大鼠认知功能的影响 行为)和/或氟哌啶醇(模拟抗精神病治疗)。

UCI-40083, a selective positive allosteric modulator (PAM) of the alpha7 nicotinic acetylcholine receptor (alpha7 nAChR), was designed and characterized by the team at UC Irvine. Its synthesis for the clinical trials and pre-clinical experiments in this NCDDDG Project will be peformed by medicinal chemists at Newport Scientific Inc., supervised by our team. We will work with Newport Scientific Inc. to conduct the assays and stability studies necessary for its formulation for human use. We will also work with Newport Scientific Inc. to support the assays in plasma and urine forthe Phase 1 and Phase 2 clinical trials. Because Phase 2 trials will be conducted in persons with schizophrenia who are treated with neurolepfic drugs, many of whom smoke cigarettes, the UC Irvine team will perform preclinical animal model studies to determine the effect of UCI-40083 on cognitive function in rats chronically treated with nicofine (to simulate smoking behavior) and/or haloperidol (to simulate antipsychofic treatment).